The National Institutes of Health is offering a federal grant opportunity titled "Developing Digital Therapeutics for Substance Use Disorders (UG3/UH3 Clinical Trial optional)". This grant aims to accelerate the development of Digital Therapeutics (DTx) to treat Substance Use Disorders (SUDs). DTx refers to clinical-grade mobile, web, or other software-based platforms designed to deliver safe and effective treatments for SUDs. The goal is to generate new, FDA authorized, disseminated treatments for SUDs by moving DTx to their next step in the development process. This opportunity allows for the focus on pre-clinical and/or clinical development and testing of new DTx or existing DTx developed for other indications. Eligible applicants include various institutions and organizations. The deadline for application submission is November 19, 2026. For more information and to apply, visit the following link: Developing Digital Therapeutics for Substance Use Disorders Grant. For any inquiries, contact NIH Grants Information at grantsinfo@nih.gov.